Purpose

The Texas A&M Center for Innovation is founded on an initial $285.6 million public-private partnership with the U.S. Department of Health and Human Services, and is designed to enhance the nation’s emergency preparedness against emerging infectious diseases, including pandemic influenza, and chemical, biological, radiological and nuclear threats.
Read More

Press Release

Texas A&M System and GlaxoSmithKline receive U.S. Government approval to establish influenza vaccine facility in Texas (March 26, 2013). GlaxoSmithKline plc and The Texas A&M University System announced today that the U.S. Department of Health and Human Services has approved the establishment of a influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, Texas.   Read More...

The Texas A&M University System